Human papillomavirus, cervical cancer, and the vaccines

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 79-84

  Tovar, John M ^a   Bazaldua, Oralia V ^b   Vargas, Leticia ^b   Reile, Erin ^c  

^a UNIVERSITY OF THE INCARNATE WORD   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cervarix ; Gardasil ; HPV bivalent vaccine; HPV quadrivalent vaccine; HPV types 6, 11, 16, 18; Human papillomavirus; Sexually transmitted diseases, viral

Indexed keywords

IMIQUIMOD; PLACEBO; PODOPHYLLOTOXIN; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ARTICLE; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CARCINOMA IN SITU; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; NAUSEA; PAPANICOLAOU TEST; PATIENT EDUCATION; PREVALENCE; RHINOPHARYNGITIS; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CARCINOMA; VIRUS TYPING; VULVA CARCINOMA; WART VIRUS; FEMALE; PATHOLOGY; REVIEW; UTERINE CERVIX TUMOR; VIRUS INFECTION;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 54049144355     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1794     Document Type: Article

References (37)

1. Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol. 2003;189(3 suppl):S3-S11. (Pubitemid 37194064)
2. Centers for Disease Control and Prevention. Twenty-five years of HIV/AIDS - United States. 1981-2006. MMWR Morb Mortal Wkly Rep. 2006;55(21):585-589.
3. Koulsky LA, Kiviat NB. Human papillomavirus infections. In; Holmes KK, Mardh PA, Sparling PF, et al. eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999:347-360.
4. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 2003;3(8):469-475. (Pubitemid 36919093)
5. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005; 32(suppl 1) S7-S15.
6. Collins S, Mazloomzadeh S. Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002; 109(1):96-98. (Pubitemid 37329328)
7. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11(6):598-603. (Pubitemid 33044469)
8. Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol. 2003; 188(3):677-684. (Pubitemid 36332433)
9. Stanley M. The end for genital human papillomavirus infections? Lancet Oncol. 2005;6(5):256-257. (Pubitemid 40590245)
10. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31(3):3-13.
11. Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. IARC Sci Publ. 1992;119:223-241.
12. American Cancer Society. Detailed Guide: Cervical Cancer. What are the key statistics about cervical cancer? Revised March 26, 2008. http://www.cancer.org/docroot/CRI/content/CRI-2-4-1X-What-are-the-key- statistics-for-cervical-cancer-8.asp. Accessed May 28, 2008.
13. Yabroff KR, Lawrence WF, King JC, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health. 2005;21(2):149-157. (Pubitemid 40463567)
14. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37(suppl 8):S4-S66.
15. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2): 153-156.
16. National Cancer Institute. SEER Cancer Statistics Review. Estimated new cancer cases and deaths for 2005. http://seer.cancer.gov/csr/1975-2002/results- single/sect-01-table.01.pdf. Accessed May 28, 2008.
17. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157(3):218-226. (Pubitemid 36152435)
18. Naud P, Matos J, Hammes L, et al. Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil. Eur J Obstet Gynecol Reprod Biol. 2006; 124(1): 110-118. (Pubitemid 43020940)
19. Gunnell AS, Tran TN, Torrang A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006; 15(11):2141-2147. (Pubitemid 44877038)
20. Chuang TY. Condylomata acuminata (genital warts). An epidemiologic view. J Am Acad Dermatol. 1987;16(2 pt 1):376-384. (Pubitemid 17013733)
21. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand. 1996;75(3):287-290. (Pubitemid 126422256)
22. Centers for Disease Control and Prevention. US Department of Health and Human Services. Sexually transmitted disease surveillance, 2006. http://www.cdc.gov/std/stats/tables/table42.htm. Published November 13, 2007. Accessed May 28, 2008.
23. Ault KA. Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine. Obstet Gynecol Clin North Am. 2003;30(4):809-817. (Pubitemid 38018639)
24. Centers for Disease Control and Prevention. Trends in sexual risk behaviors among high school students - United States, 1991-2001. MMWR Morb Mortal Wkly Rep. 2002;51(38):856-859.
25. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002;29(11):725-735. (Pubitemid 35266418)
26. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645-2654. (Pubitemid 43920838)
27. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(suppl 2):S210-S224. (Pubitemid 35178333)
28. Gardasil [package insert]. Merck and Co., Inc. Whitehouse Station, NJ; 2008. https://www.merckvaccines.com/gardasilProductPage-frmst.html. Accessed May 28, 2008.
29. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459- 1466. (Pubitemid 44863348)
30. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278. (Pubitemid 40590263)
31. Koutsky LA, Ault KA, Wheeler CM, et al; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
32. Harper DM, Franco EL, Wheeler C, et al; GlaxoSmithKline HPV Vaccination Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-1765. (Pubitemid 39488060)
33. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927. (Pubitemid 46740302)
34. Garland SM, Hernandez-Avila M, Wheeler CM, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
35. Markowitz LE, Dunne EF, Saraiva M, Lawson HW, Chessonll, Unger ER; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practice (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
36. American College of Obstetricians and Gynecologists (ACOG). HPV vacciue-ACOG recommendations. August 2006. http://www.acog.org/departments/dept- notice.cfm?recno=7&bulletin=3945. Accessed May 12, 2008.
37. Centers for Disease Control and Prevention. Syncope after vaccination-United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457-460.